

December 10, 2024

Dear Valued Customer,

We are writing to provide an update on BP Cuff supply continuity. We understand the critical importance of supply continuity and are committed to providing transparent and proactive communications. We are providing updates in alignment with our direct outreach on [Baxter.com](https://www.baxter.com).

Baxter's manufacturing of BP Cuffs has continued to run on a 24/7 operation, including through the U.S. Thanksgiving holiday, and will continue at this rate every day in December with the exception of Dec. 25. We are continuing to prioritize SKU configurations of the highest demand while remaining agile with our production plan as needed.

Current allocation guidance by category is listed below. Supply volumes to our distributors are determined based on historical ordering from April 2024 to Sep. 2024. As a reminder, these recommendations are in place to navigate unnaturally high order volumes and help achieve an equitable, efficient and responsible distribution of available supply.

Blood Pressure Cuff Type	Historical Allocation Guidance (Nov 18, 2024)	Current Allocation Guidance (Dec 16, 2024)	Anticipated Allocation (Jan, 2024)
FlexiPort Standardization/RAW Soft	60%	75%	85%
FlexiPort Fully-Configured Soft	20%	20%	20%
Trimline Soft	80%	90%	100%
FlexiPort Standardization/RAW Vinyl	60%	75%	85%
FlexiPort Fully-Configured Vinyl	20%	20%	20%
Trimline Vinyl	80%	90%	100%
Neonatal Soft	100%	100%	100%
Neonatal Vinyl	100%	100%	100%
FlexiPort Standardization/RAW Reusable	90%	90%	100%
FlexiPort Fully-Configured Reusable	100%	100%	100%
Trimline Reusable	100%	100%	100%
Two-Piece Reusable	100%	100%	100%

The weekly allocation process and communications with our distributors remain consistent with prior weeks, including an upcoming update regarding supply details that will be shared with distributors later this week.

As we work to mitigate the impact of this issue on you and your patients, we are pleased to share that we are moving forward with our capacity expansion plan, including diversification of our manufacturing locations. The capital equipment investments made to accelerate backlog recovery will be installed in the U.S. We will continue to meet the needs of our customers through our manufacturing facilities in Mexico, with the added location in the U.S. coming online in early 2025.

Should your team need additional information on cleaning and disinfecting protocol, please route those questions to HST_Medinfo@baxter.com.

Thank you for your continued patience and understanding as we navigate this situation.

Sincerely,

Your Baxter Representative